elagolix (Orilissa)

Indications

• endometrosis pain

Dosage

• 150 mg PO QD for up to 24 months
• 200 mg PO BID for up to 6 months

Adverse effects

• dose-dependent decrease in bone mineral density
  • osteopenia, osteoporosis

Mechanism of action

• gonadotropin-releasing hormone antagonist

More general terms

• hormone antagonist
• endocrine agent

Component of

• elagolix/estradiol/norethindrone

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11250647
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=24785956
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=129317828